Upcoming Trends in PET Oncology

1. Tumor-Specific Targeting 1a. [68Ga]Ga-PSMA-11: Targets prostate-specific membrane antigen (PSMA) in prostate cancer for staging and recurrence detection. 1b. [68Ga]Ga-FAPI-04: Targets fibroblast activation protein (FAP) in solid tumors like pancreatic and breast cancer. 1c. [68Ga]Ga-DOTA-TATE: Targets somatostatin receptors in neuroendocrine tumors.

2. Theranostics 2a. [177Lu]Lu-PSMA-617: Used after imaging prostate cancer with [68Ga]Ga-PSMA-11. 2b. [177Lu]Lu-DOTA-TATE: Used after imaging neuroendocrine tumors with [68Ga]Ga-DOTA-TATE.

3. Immunotherapy 3a. [89Zr]Zr-atezolizumab: Assesses programmed death-ligand 1 (PD-L1) expression for checkpoint inhibitor therapies. 3b. [18F]FDG: Evaluates metabolic response to immunotherapies like Chimeric Antigen Receptor (CAR) T-cell therapy and nivolumab.

4. Hormone-Dependent Cancers 4a. [18F]FES: Targets estrogen receptors in breast cancer for therapy planning. 4b. [18F]FDHT: Targets androgen receptors in prostate cancer for therapy planning.